SarahChen_PharmD said:Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…
Mine went the same way, slower. I had assumed I was the exception until I read this.
dan_philly said:I want to bring up the cardiovascular angle on cardiovascular risk.
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 4 of 5 diagnostic criteria to meeting ZERO after 12 months of treatment.
The 5 criteria (and my journey):
Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.
The figures, for anyone assembling their own picture. For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and subcutaneous bioavailability near 89%. Those four numbers explain most of the questions people ask about timing.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after dan_philly’s answer:
How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?
Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Thread quality here is what the rules are for. Keep it up.